Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Chaka, A post can be stickied only within 48 hours of when it was posted. I can't add it at this point. Sorry about that.
Thank you Ultimate. I've been slow posting lately.
Should be nice to just sip by itself.
I'd love to try it.
At Caskers:
FUN, That sounds like a great plan!
All excellent points, FUN.
It will happen. ROX will be acquired.
At Caskers:
That's a teriffic piece for Jefferson's. How much circulation does this guy get?
Same here.
Sounds like a missed opportunity.
Was this variety ever included in one of the "experimental" 5-packs?
Caskers promoting Jefferson's Grand Selection Chateau Suduiraut Sauternes Cask Finish:
BD, I’d say primary reason for the drop would be the lack of news at a thinly traded early stage bio with little visibility. Second, I suspect that management has been slowly dripping out some shares thru Aspire, which has the effect of putting slight downward pressure on the share price.
Not much going on publicly. Hope to see some news (good) soon.
Chris, Thanks for the invitation and a Merry Christmasto you.
OK, good. Welcome aboard.
Hi Chaka,
This may be a low-priced penny stock, but it has quality goods in the form of BIV-201. It's not a high-volume trading vehicle with lots of shares changing hands daily, tho I appreciate your enthusiasm.
The holders I know are patient long-term investors who believe in having a reasonable investment here and being on board for when Jonathan Adams finishes pushing BIVI to the top of the hill. Then things will speed up. I hope you have a core position here and are adding when opportunities present themselves.
I agree that a sharp price increase could happen quickly, but am not attempting to time the market for this stock. If you are a "qualified investor" I would suggest you contact Jonathan about whether shares and warrants are still available in their PIPE.
This is true, IMHO. Massive returns from BIVI are possible. The issue is similar to watching a champion hurdler run their race. They need to surmount each hurdle easily and cleanly and nothing else messes them up.
Hi Gov,
I know you are impatient with IPIX progress and feel that their management has been too slow.
In defense of Leo and Menon over at IPIX, BIVI has a known drug which has been observed, while in off-label use, to dramatically reduce ascites and to have negligible safety risks. Jonathan - the BIVI CEO - is very methodically dotting every "i" and crossing every "t" in running thru the steps the FDA needs to see to show that the drug (approved in Europe but not in the US) is safe and has the effect of reducing ascites. In a more logical world, the FDA would have looked at the data from Europe and said "sure, lets approve the drug."
Jonathan initially started with capital from a few founders, added to the shell of the company into which it was merged and then collected more capital from angel investors, myself (and perhaps yourself?) included. After that, Jon moved on to a similar deal with Aspire for incremental financing as Leo did.
At IPIX, Leo has Kevetrin and Brilicidin which are both novel drugs, Prurisol is a novel formulation of a known drug used for HIV. FDA is really just making IPIX jump thru more hoops than BIVI, IMHO. EDIT: WE know Dana Farber was extremely slow in doing the Ph1 study. I do not think that was Leo's fault.
Fun, You were prescient about this.
Sounds good.
AndCaskers pushing Jeff's Ocean Cask Strength:
Excellent analysis and explanation, FUN.
One point I would make is that 1.46 cases of GGB per week in each of 5000 Walmarts and grocery stores may not be what it seems. 1.46 does not sound so great, but there may be fewer than 5000 stores as the numbers gradually increase along with production capacity of GGB.
Suppose that, on average, there were one-third that number of stores during the quarter. That equates to roughly 4.3 cases of GGB per week per store. I bet that GGB sales will - as you note - ramp up in sequential quarters. Two-thirds of the stores next quarter and all 5000 the next.
Jefferson's Wood Experiment Collection
Inspired by a Missouri wine cooperage, this selection features five of the 13 small batch bourbon whiskeys from Jefferson's experimental Wood series. $119.99
The principal author of the Declaration of Independence and one of the greatest Founding Fathers, Thomas Jefferson was elected the third President of the United States in 1800. During his tenure, Jefferson authorized the purchase of the Louisiana Territory, dispatched Lewis and Clark westward to explore the remainder of the continent and repealed the Whisky Excise Tax.
After Jefferson retired from public office in 1815, he often tended to the garden that he had cultivated on his Monticello estate. At the time, it was customary for wealthy farmers, including Jefferson, to distill the excess grains they harvested from their farms into spirits (George Washington was one of the country’s largest distillers of rye whiskey). As a result, each farmer’s spirits were unique and reflected the local terroir of their farm. The Jefferson’s brand pays homage to Jefferson and the exquisite whiskey he distilled.
Founded in 1997, Jefferson’s is the brainchild of Trey Zoeller and his father Chet, a famed bourbon historian. Continuing a family tradition that dates as far back as the 18th century -when Trey’s 8th generation grandmother was arrested in 1799 for the “production and sales of spirituous liquors.”
Generations later, the father-son duo chose to personify the brand in the spirit of Thomas Jefferson—who was renown his curious nature and love of experimentation. Jeffersons is constantly expanding their horizons with new and innovative ways of looking at whiskey, and how it interacts with wood. At this intersection of art and experimentation, lies inspiration. The Wood Experimental Collection was inspired by an enlightening trip to a wine cooperage in Missouri.
Wine barrels are almost exclusively toasted oak, as opposed to bourbon’s charred, brand-new barrels, which yield a high-oak flavor profile. This is what inspired Trey Zoeller to embark on an experimental journey with a 4-year-old bourbon, aging it in new charred white oak barrels, and finishing it in 13 different environments/vessels.
"Over a period of 32 months, we charted the characteristics of each experiment monthly and analyzed how the different treatments have affected the outcome of the final whiskey” (producer).
This selection features five of the 13 small batch experimental bourbon whiskeys: #3, #4, #6, #10, and #12, each vessel imparting a distinct and intriguing character onto the spirit. Wood exp. no.3 was finished in new 60-gallon American oak barrels with a low, deep impact toast profile. Wood exp. no.4 was finished in a new standard whiskey barrel with medium char, infused with heavily charred American oak cubes. Wood exp. no.6 was finished in a new standard whiskey barrel with a light-medium char, infused with lightly toasted American oak staves. Wood exp. no.10 is finished in a hybrid 60 gallon French and American barrel with a low, deep impact toast profile. Wood exp. no.12 is finished in an original bourbon barrel, with toasted oak inserts
https://www.caskers.com/jefferson-s-wood-experiment-collection/?utm_source=Sailthru&utm_campaign=Daily&utm_medium=Email&utm_content=Final&utm_term=daily_all_wo_welcome
Not bad Q2 results.
BD, I don't recall if I mentioned that the CEO, Jonathan Adams is quite willing to have a focused discussion about what they are doing and where they are heading. I am also quite impressed about the capabilities of the folks Jonathan has added to staff and how inexpensively they are moving forward.
You're quite welcome.
BD, In essence, the retricted shares CAN'T be sold publicly until BIVI releases the restrictions.
The last annual report says:
"We have a large number of restricted shares outstanding, a portion of which may be sold under Rule 144 which may reduce the
market price of our shares.
Of the 87,160,001 shares of Common Stock currently issued and outstanding, and assuming no Warrants are exercised, 77,022,069
shares are held by non-affiliates and 10,137,932 are owned by affiliates of the Company, consisting of our officers and directors and a large shareholder. All of these securities are deemed “restricted securities” within the meaning of Rule 144 as promulgated under the Securities Act. Other than the 5,000,000 shares previously issued to the selling security holders in the Private Placement and other than the 5,000,000 shares underlying the Warrants purchased in the Private Placement, none of the above described shares are being offered for sale in this prospectus. Consequently, the sale of such shares is subject to Rule 144.
It is anticipated that all of the “restricted securities” will be eligible for resale under Rule 144. In general, under Rule 144, subject to the satisfaction of certain other conditions, a person, who is not an affiliate (and who has not been an affiliate for a period of at least three months immediately preceding the sale) and who has beneficially owned restricted shares of our common stock for at least six months is permitted to sell such shares without restriction, provided that there is sufficient public information about us as contemplated by Rule 144. An affiliate who has beneficially owned restricted shares of our common stock for a period of at least one year may sell a number of shares equal to one percent of our issued and outstanding common stock approximately every three months.
The respective holding periods for the shares issued to affiliates and non-affiliates holding restricted securities commenced and were
issued between May 17, 2013 and June 30, 2013. The possibility that substantial amounts of our Common Stock may be sold under
Rule 144 into the public market may adversely affect prevailing market prices for the Common Stock and could impair our ability to
raise capital in the future through the sale of equity securities."
The 2013 shares referred to date from when NanoAntibiotics (NNAB, the predecessor incarnation to BIVI) was founded and funded. I do not have those shares, except for a few which came on to the market for public sale and those were entirely speculation on my part based on the owners and the source of the IP being pursued. Most of those holders still hold their shares, while a few sold their shares to the present management.
Without my going back to the agreement under which I purchased my larger block of restricted shares, I'm unsure of the date and schedule under which the trading restrictions will be released. Rest assured, I am still just a small holder.
Were I you, I would go thru all the documents they make available online and then send an email to management, asking Jonathan or whomever to give you a call for a short discussion. I would lay out your questions in the email, so you can both minimize the time required.
I am not concerned about the restrictions as I am not a trader. I intend to hold until we have a deal for either the drug or for the entire company. Those are the catalysts, other than sale thru Aspire. The daily fluctuations in price simply present periodic opportunities to acquire more shares. As an angel investor, I am accustomed to long holding periods. Even removal of the restrictions
Only traders would be flipping their shares for pennies, when many dollars wait at the end of the line. All IMHO.
BD, I've spoken a couple times with management and have confidence in their being able to bring a proven drug in Europe thru to approval in the US. I'm sure, with the experienced people they have brought on board, their have the contacts and wherewithal to sell either the drug outright or get a larger pharma to buy us out. This is not a novel, untested product.
I own both publicly traded shares (from the earlier incarnation of the public company and purchased more recently as BIVI) and locked up shares purchased with warrants as part of their initial PIPE.
I think you'll find that most shares outstanding are locked up and not yet tradeable, like mine. Hence the low volume being traded. BIVI also now has an agreement with Aspire Capital, whereby BIVI management can direct Aspire to buy up to a certain limited number of shares daily.
So, what you may be seeing are a few shares from Aspire reselling into the market but not selling so many shares as to cut the legs out from under the stock. There is not a large overhang of shares to trade, thus it's hard for flippers to scare up enough shares to trade constantly.
Slow, steady accumulation is called for if you share my views.
Fun,
My guess would be that really large customers, like Walmart, which might bypass our distributors as "direct customers," would be paying just about the same price as the distributors.
My estimate stands, but like you, I'd love for the production to be 10,000 cases.
You're welcome.
I'm certainly open to corrections and alternate estimates.
Trying to be conservative and assume the distributors and retailers share a nice margin of $80/bottle.
Cost of goods sold to Castle Brands should be about $50 or less. Price to distributors should be roughly $120. So ROX should make roughly $70/bottle times 10,000 or $700,000 out of the $2 million, assuming my approximations are close enough.
Every $10 higher margin per bottle is an added $100,000 to ROX.
Other than thru our distributors, I would imagine it is a closely guarded secret.
Caskers offering Goslings Family Reserve Old Rum:
https://www.caskers.com/gosling-s-family-reserve-old-rum/?utm_source=Sailthru&utm_campaign=Daily&utm_medium=Email&utm_content=Final&utm_term=daily_all_wo_welcome
It is a tough choice.
Sounds good for our next trip to Philly.
why the drop today?
Nicest thing anyone said about me today. Thank you.